Title
Category
Credits
Event date
Cost
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updates in Prognosis and Treatment
  • Chronic Lymphocytic Leukemia
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The prognostic significance of molecular and cytogenetic variables vary depending on the treatment regimens and clinical outcomes being evaluated. A precise understanding of the prognostic significance of these variables is essential for the appropriate selection of patients who might benefit from specific targeted therapies with small molecule inhibitors.
What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma?
  • Hodgkin Lymphoma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Given the high cure rate of classic Hodgkin lymphoma, clinical trials strive to reduce potential long-term toxicities of treatment. Novel agents such as antibody-drug conjugates and immune checkpoint inhibitors have become part of front-line treatment recommendations for advanced stage classic Hodgkin lymphoma over the last several years, allowing for reduction in toxicities such as pulmonary toxicity associated with bleomycin and secondary cancer risk from agents such as procarbazine.
Recorded Presentation from the NCCN Pharmacy Updates: Advances in Neoadjuvant Treatment Options in Locally Advanced and Metastatic Rectal Cancer with Deficient Mismatch Repair
  • Rectal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Treatment options for locally advanced or metastatic rectal cancer are evolving constantly. It is important for care teams to have an understanding of the current treatment approaches, toxicity management, and appropriate supportive care recommendations throughout a patient’s treatment course.
Renal Cell Carcinoma: Evolving Perspectives on Optimal Treatment
  • Kidney Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with renal cell carcinoma (RCC).
Archived NCCN Tumor Boards: Treatment Selection Strategies and Barriers to Clinical Care in Metastatic Breast Cancer
  • Breast Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
Clinicians need to understand the diverse and evolving SDOH landscape, especially as it relates to clinical trial access for individuals with metastatic breast cancer (mBC), and they need to consider potential strategies to address SDOH to ensure equitable care and improve overall outcomes for patients with mBC.
Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent and Near-Future Changes
  • Bladder Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with bladder cancer.
Are You Applying the Latest Guidelines for Multiple Myeloma? Experts Discuss Equitable, Evidence-Based Care
  • Multiple Myeloma
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ABIM Medical Knowledge
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
$0.00
Join us for this case-based, interactive on-demand program featuring expert perspectives on treatment for patients with newly diagnosed and relapsed/refractory multiple myeloma.
Archived NCCN Tumor Boards: Acute Myeloid Leukemia: The Importance of Individualized Patient Care
  • Acute Myelogenous Leukemia
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
Individualized patient care is highly important in acute myeloid leukemia (AML) therapy to ensure the most effective treatment regimens can be selected for appropriate patients.
Recorded Presentation from Optimizing Patient Outcomes - Beyond the Package Insert: Appropriate Interpretation of Testing Results for Targeted Therapy Selection
  • Rectal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Education on this topic can provide useful information on how to find the necessary information required to accurately recommend the best therapy option.
Biomarker Testing and Interpretation after Breast Cancer Diagnosis
  • Breast Cancer
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Clinicians can benefit greatly from understanding the technology involved in genomic and molecular testing and profiling assays and their interpretation. Clinicians should know what, when, and how to test and how to make subsequent informed, patient‐personalized treatment decisions. Accurate interpretation of results is critical — over-interpretation or misinterpretation will lead to treatment of patients with ineffective and expensive therapies, negatively impacting patient outcomes.

Pages